

# Tyng-Yuan Jang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8598857/publications.pdf>

Version: 2024-02-01

35  
papers

269  
citations

1307366

7  
h-index

1058333

14  
g-index

35  
all docs

35  
docs citations

35  
times ranked

388  
citing authors

#	ARTICLE	IF	CITATIONS
1	On-treatment gamma-glutamyl transferase predicts the development of hepatocellular carcinoma in chronic hepatitis B patients. <i>Liver International</i> , 2022, 42, 59-68.	1.9	10
2	Serum <i>Wisteria floribunda</i> agglutinin-positive Mac-2-binding protein expression predicts disease severity in nonalcoholic steatohepatitis patients. <i>Kaohsiung Journal of Medical Sciences</i> , 2022, 38, 261-267.	0.8	2
3	Towards a safe hospital: hepatitis C in-hospital micro-elimination program (HCV-HELP study). <i>Hepatology International</i> , 2022, 16, 59-67.	1.9	5
4	Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha-fetoprotein levels. <i>Cancer Medicine</i> , 2022, 11, 104-116.	1.3	7
5	Dynamics of cytokines predicts risk of hepatocellular carcinoma among chronic hepatitis C patients after viral eradication. <i>World Journal of Gastroenterology</i> , 2022, 28, 140-153.	1.4	6
6	Clinical characteristics and treatment outcomes of SARS-CoV-2 delta variant outbreak, Pingtung, Taiwan, June 2021. <i>Journal of the Formosan Medical Association</i> , 2022, 121, 1767-1772.	0.8	7
7	Outreach onsite treatment with a simplified pangenotypic direct-acting anti-viral regimen for hepatitis C virus micro-elimination in a prison. <i>World Journal of Gastroenterology</i> , 2022, 28, 263-274.	1.4	10
8	Suppression of hepatitis C virus replication during COVID-19 infection. <i>Kaohsiung Journal of Medical Sciences</i> , 2022, 38, 394-395.	0.8	3
9	Itemization difference of patient-reported outcome in patients with chronic liver disease. <i>PLoS ONE</i> , 2022, 17, e0264348.	1.1	2
10	The compound annual growth rate of the fibrosis index in chronic hepatitis B patients. <i>Kaohsiung Journal of Medical Sciences</i> , 2022, , .	0.8	0
11	Low disease awareness as a contributing factor to the high prevalence of hepatitis C infection in Tzukuán, a hyperendemic area of southern Taiwan. <i>Kaohsiung Journal of Medical Sciences</i> , 2022, , .	0.8	2
12	Why cannot Taiwan be COVID-19 free?. <i>Journal of the Formosan Medical Association</i> , 2022, 121, 2365-2366.	0.8	2
13	Liver injury caused by SARS-CoV-2 Delta and Omicron-variant in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2022, , .	0.8	6
14	Amelioration of glucose intolerance through directly acting antiviral agents in chronic hepatitis C cirrhotic patients without overt diabetes. <i>Kaohsiung Journal of Medical Sciences</i> , 2022, 38, 897-906.	0.8	3
15	Role of hepatitis D virus in persistent alanine aminotransferase abnormality among chronic hepatitis B patients treated with nucleotide/nucleoside analogues. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 303-310.	0.8	8
16	Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 186-196.	4.5	9
17	Concordance of SVR12, SVR24 and SVR durability in Taiwanese chronic hepatitis C patients with direct-acting antivirals. <i>PLoS ONE</i> , 2021, 16, e0245479.	1.1	5
18	Evolutionary seroepidemiology of viral hepatitis and the gap in hepatitis C care cascades among uraemic patients receiving haemodialysis in Taiwan—the Formosa-Like Group. <i>Journal of Viral Hepatitis</i> , 2021, 28, 719-727.	1.0	5

#	ARTICLE	IF	CITATIONS
19	Genotype distribution, clinical characteristics, and racial differences observed in chronic hepatitis C patients in Pingtung, Taiwan. <i>Journal of the Chinese Medical Association</i> , 2021, 84, 255-260.	0.6	6
20	Comorbidities in patients with chronic hepatitis C and hepatitis B on hemodialysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2261-2269.	1.4	2
21	Changing epidemiology and viral interplay of hepatitis B, C and D among injecting drug user-dominant prisoners in Taiwan. <i>Scientific Reports</i> , 2021, 11, 8554.	1.6	11
22	Role of hepatitis D virus infection in development of hepatocellular carcinoma among chronic hepatitis B patients treated with nucleotide/nucleoside analogues. <i>Scientific Reports</i> , 2021, 11, 8184.	1.6	17
23	Seroreversion of hepatitis B surface antigen among subjects with resolved hepatitis B virus infection: A community-based cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 3239-3246.	1.4	0
24	The Prevalence and Serological Association of Hepatitis D Virus Genotypes in Taiwan. <i>Pathogens</i> , 2021, 10, 1227.	1.2	0
25	Improvement of hyperuricemia in chronic hepatitis C patients receiving directly acting antiviral agents. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 473-481.	1.4	7
26	Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B. <i>American Journal of Gastroenterology</i> , 2020, 115, 271-280.	0.2	72
27	Hypopharyngeal and Laryngeal Lesions in a Patient with Chickenpox. <i>Ear, Nose and Throat Journal</i> , 2020, 100, 014556132093231.	0.4	0
28	Serial serologic changes of hepatitis D virus in chronic hepatitis B patients receiving nucleos(t)ides analogues therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1886-1892.	1.4	8
29	Less liver fibrosis marker increment in overweight chronic hepatitis B patients observed by age-adjusted Fibrosis-4 Index. <i>BMJ Open Gastroenterology</i> , 2020, 7, e000543.	1.1	3
30	The applicability of non-invasive methods for assessing liver fibrosis in hemodialysis patients with chronic hepatitis C. <i>PLoS ONE</i> , 2020, 15, e0242601.	1.1	5
31	The prognosis of bulky hepatocellular carcinoma with nonmajor branch portal vein tumor thrombosis. <i>Medicine (United States)</i> , 2019, 98, e15066.	0.4	8
32	Association of hyperuricemia with disease severity in chronic hepatitis C patients. <i>PLoS ONE</i> , 2018, 13, e0207043.	1.1	13
33	Hepatocellular carcinoma metastatic to kidney mimicking renal cell carcinoma. <i>Kaohsiung Journal of Medical Sciences</i> , 2017, 33, 161-162.	0.8	2
34	Seroprevalence and clinical characteristics of viral hepatitis in transfusion-dependent thalassemia and hemophilia patients. <i>PLoS ONE</i> , 2017, 12, e0178883.	1.1	18
35	Four weeks of paritaprevir/ritonavir/ombitasvir plus dasabuvir encountering dengue fever resulted in sustained virological response in an HCV patient. <i>Medicine (United States)</i> , 2016, 95, e5304.	0.4	5